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This perspective paper examines the challenges of implementing regenerative medicine (RM) therapies
within hospitals and clinics. Drawing on recent work in the social sciences, the paper highlights dynamics
within existing healthcare systems that will present both hindrances and affordances for the implemen-
tation of new RM technologies within hospitals and clinics. The paper argues that identifying suitable
locations for cell- and gene-therapy treatment centers requires an assessment of their institutional readi-
ness for RM. Some provisional criteria for assessing institutional readiness are outlined, and the paper
will suggest that it is necessary to begin developing a program for the phased introduction of RM in the
longer term.
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Regenerative medicine (RM) therapies, particularly those that are commonly referred to as advanced cell and
gene therapies, are in many ways significantly different from existing, conventional therapeutic products and
techniques [1]. Cell, tissue or gene-based technologies have the potential to provide therapeutic relief for a range
of disorders for which there is currently severe unmet clinical need [2], but the sensitivity and complexity of these
technologies presents a range of innovation challenges [3], and commentators have suggested that promising RM
technologies are particularly susceptible to the ‘valley of death’ [4]. Many of these challenges relate to upscaling and
manufacturing, regulatory requirements, reimbursement and commissioning [5]. These have been well characterized
in recent reviews of the RM field [6], and government-supported initiatives such as the UK’s Cell and Gene Therapy
Catapult have been launched to mitigate these and facilitate commercialization [7]. Recent reports, however, have
identified an additional area of concern: the clinical adoption of RM therapies within existing healthcare systems [8,9].
Hospitals and clinics within contemporary healthcare systems have developed systems to accommodate drug- and
device-based therapies and surgical interventions, and they may, then, be poorly suited to implementing cell-, tissue-
and gene-based treatments. There is, in other words, a degree of incommensurability between existing healthcare
providers and the exigencies of providing RM therapies [10].
A consequence of this mismatch is that potential investors have difficulties envisaging a clear pathway to
commercial and clinical success [11]. This uncertainty represents a risk to the momentum that currently characterizes
RM in the UK, Canada, various US states and elsewhere. Hence, while the majority of promising RM therapies
are still in the early phases of clinical development [12], commentators have argued that it is necessary to address the
potential challenges of clinical delivery in the immediate future [8,9,11]. In this vein, this paper examines the challenges
of implementing RM technologies within existing systems of delivery, and it offers some guiding reflections on how
such challenges may responsibly be managed. RM represents a diverse range of technologies and techniques, many of
which can be characterized as disruptive innovations [13]. The ecosystem of biomedical innovation is being redrawn as
policy makers and other stakeholders attempt to facilitate the translation of promising developments in the lab into
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useful, cost-effective clinical tools: new regulatory pathways are being forged, novel interdisciplinary collaborations
are being encouraged and new innovation-facilitating agencies have been established [14]. Healthcare providers
are also implicated in these changes as new clinical delivery infrastructures will be required. The considerable
financial strain experienced by providers and healthcare systems in many countries, however, could hamper the
required transformations. It is necessary, then, to anticipate likely challenges and tensions of implementation, and
to identify potential opportunities, so that resources and expertise can be responsibly deployed. Hence, in the
following section, this paper will provide a brief overview of recent research in the social sciences on what is often
referred to as the problem of ’technology adoption’ in healthcare. This body of work highlights some of the general
dynamics within existing healthcare delivery infrastructures that present both hindrances and affordances for the
implementation of new technologies. These are highly relevant for RM, but as the paper will illustrate, promising
RM therapies present an additional set of challenges. In the section ‘Advanced Therapy Treatment Centers’, this
paper will provide a brief overview of recent proposals to establish specialist cell and gene therapy treatment centers
within the UK. In order to prompt and contribute to discussion on the substantive dimensions of these centers,
the paper will identify important precedents and opportunities within existing healthcare arrangements. The paper
will argue that identifying suitable locations for cell and gene therapy treatment centers will require an assessment
of their ’institutional readiness’ (IR) for RM. Additionally, the paper will specify some relevant criteria for assessing
IR. In the final section, the paper will propose that the longer-term implementation of RM therapies within the
healthcare system should occur in three sequential phases. A preliminary sketch of the activities required at each
phase to ensure that the healthcare system is responsibly transformed will be provided.
The challenge of technology adoption in healthcare
Conventional and now largely outdated understandings of innovation as a linear process have tended to portray
the adoption of new technologies within contexts as a relatively simple process. This is perhaps most apparent
in the ‘technology readiness’ framework, for example [15], in which at the end of the innovation process, a fully
developed and discrete technology or system is straightforwardly implemented in relevant contexts [16]. Within the
last decade, however, there has been a widespread recognition among policy makers and the biomedical community
that technology adoption can be a problematic and disruptive process that necessitates active engagement [17]. This
interest in technology adoption has been prompted by a confluence of factors which include a political concern with
variations in service quality within healthcare systems, high-profile technology adoption failures and perhaps most
notably, the emerging focus on facilitating translational medicine. Much of the discourse surrounding translational
medicine and accelerating access to promising new treatments emphasizes the importance of engaging end users
(front-line clinicians) in upstream innovation processes, so that the new technology, technique or system will be
better configured for actual clinical use, for example [9,18].
This policy interest in technology adoption has prompted social science research into specific adoption processes
in medicine involving a range of innovations such as IT systems, surgical procedures, diagnostics and medical
devices. The general finding from this literature is that healthcare contexts are characterized by considerable
complexity and heterogeneity [19]: any given healthcare provider is constituted by often obdurate infrastructures
and routines, multiple professions with sometimes conflicting viewpoints and interests, funding pressures and
resource constraints, all of which can complicate the uptake of new technologies and practices [17]. The more
specific findings of this body of work are highly relevant for the implementation of RM technologies.
First, the adoption of a technology, practice or system will be severely hindered if it does not align with professional
and institutional interests and values. For example, the uptake of telemedicine within psychiatry (which was much
championed in UK healthcare policy) was resisted by front-line health professionals who felt that it inhibited their
ability to provide attentive and effective care [20]. The importance of institutional interests is illustrated with the
adoption of a robotic surgical system for prostatectomy by health providers in many parts of the world [21,22]. In the
UK, the robotic system has not been recommended by NICE for prostatectomy because as yet there are insufficient
data that it offers meaningful clinical or cost advantages over conventional procedures [23]. Despite this, National
Health Service (NHS) hospitals – as with other hospitals in Europe – have enthusiastically embraced the technology
and have creatively sourced funding to purchase and maintain the system. The principal reason for this is that the
high profile of the system as being ‘high-tech’ and ‘futuristic’ helped hospitals to publicly position themselves as
being at the forefront of medical innovation [21,22]. The robotic system, in other words, had an identity that aligned
with institutional interests.
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Second, social science studies have also illustrated that the distinction between cost–effectiveness and affordability
is highly relevant to adoption. This is illustrated by Celution R© System within the UK, a cell preparation device
that is used in soft tissue repair such as partial breast reconstruction following cancer treatments (The Celution
System is manufactured by the San Diego-based Cytori Therapeutics, Inc. [CA, USA]). The system was deemed
cost-effective by the NHS Technology Adoption Centre in 2011 [24], and surgeons using the device have found
it to be highly useful, but its uptake in the NHS has been limited. One reason proffered for this (in addition to
some regulatory uncertainty surrounding the device) was that it has a relatively high upfront cost and is therefore
perceived by NHS trusts as unaffordable [25]. The payment structures and fixed budgets that characterize many
universal healthcare systems such as the UK’s NHS mean that large upfront costs cannot easily be offset by overall
savings in the longer term [26] although this may be possible for healthcare systems based on national or private
insurance. Successful technology adoption is, then, dependent on a good business case that accounts for local
budgeting and finance mechanisms.
And third, the adoption of technology may also be hindered by differences in opinion among health professionals
over what counts as ‘evidence’. As Madden has illustrated, clinicians in some specialties are often more likely to be
influenced by the testimony of their colleagues than evidenced-based medicine [27]. Similarly, clinicians pioneering
and advocating the use of deep-brain stimulation as a treatment for dystonia in children are having to challenge
existing clinical assessment measures and promote the use of what they believe to be more meaningful assessments,
which provide better proof of the therapy’s effectiveness [28,29]. Wider adoption of deep-brain stimulation in
pediatric neurology will depend on their ability to redefine what ’counts as evidence’.
These examples illustrate that the demonstration of a technology’s cost–effectiveness and clinical utility (e.g., via
a clinical trial) will not guarantee its successful adoption; other social and organizational factors, such as professional
interests, institutional prestige and budgetary models, will constrain or enable adoption practices. More generally,
these examples illustrate that a successful, innovative technology, practice or procedure in medicine is not a discrete
thing in itself. Rather, it is an institutionally sanctioned ‘change in the structure of delivery services’ [30]. Implemen-
tation scholars such as May, Greenhalgh et al. have explored the dynamics and practices that are required to bring
about such change [31–34]. It requires, May argues, that the innovative technology, practice or procedure is actively
embedded within a context (itself never static) via the ongoing work of creative agents (such as health professionals).
This requires collective effort from diverse agents (such as front-line health professionals, administrators, managers)
who need to be actively enrolled in the project: workloads and goals need to be coordinated and aligned with the
requirements and opportunities presented by the new technology, practice or procedure [30,35]. May argues that the
formation of systems for monitoring and evaluation are especially important for successful adoption, as they permit
the collective, reflective appreciation of the innovation and thus ongoing re-enrollment of key stakeholders. These
dynamics identified by May are important elements of what we will describe in a later section as IR.
Speciic adoption challenges relating to RM
The examples from social science research discussed above highlight adoption dynamics that are highly relevant
for RM. Many promising RM technologies on the horizon, for example, are likely to be high cost and hence
possibly unaffordable within some existing payment arrangements [36,37]. Institutional interests are also likely to
be important: existing studies have illustrated that some organizations have strategically positioned themselves
as ‘pioneers’ in RM [25]. And, uncertainties surrounding evidence of clinical and cost–effectiveness have already
hindered the adoption of some advanced therapies (specifically ChondroCelect R© and MACI, competing products
for treating cartilage defects) [25,38]. The complexity and novelty of RM products and techniques, however, presents
an additional set of more specific adoption challenges.
First, specialist infrastructure and expertise are required to supply (transport and store) RM products, and to
prepare products at the clinic. Some products, for example, will require cryogenic cold-chain transportation and
specialist-thawing systems at the point of clinical delivery. Appropriate quality-assurance (QA) mechanisms will also
be needed. Many existing hospitals within the UK’s NHS, for example, lack this infrastructure and expertise [39].
Second, some products (particularly autologous products) will necessitate new manufacturing arrangements, a
process of scale-out rather than scale-up. While some allogeneic products will have centralized manufacturing,
other products will require new redistributed manufacturing arrangements such as the ‘hub and spoke’ model.
Some products, particularly autologous products, will need to be either partially of fully manufactured near the
patient. This will require an onsite, or near-to-site GMP-licensed manufacturing space, linked to any existing
Pharmacy Manufacturing Unit or cell laboratory. Such facilities are expensive to run, and adhering to the required
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regulatory guidelines can be onerous. On-site manufacturing will also require expensive bioprocessing equipment
with appropriate validation and QA-compliant systems. If manufacturing of advanced cell and gene therapies
is to be cost-effective, then automated, modular, closed cell separation and expansion systems will be required.
These will represent significant upfront costs, and while there are such systems currently available on the market
(such as Miltenyi Biotec’s ‘CliniMACS Prodigy System’), more innovation in this area is needed. An additional
layer of complexity here is the dynamic nature of the highly innovative field of RM. It is likely that after initial
introduction, manufacturing processes will be subject to ongoing improvements and therapies will be incrementally
adapted and customized. Healthcare settings and regulation will need to be sufficiently flexible for such therapies
that may change from year to year. Fourth, it is likely that in some cases a hospital or a clinic will act as a cell or
tissue procurement service for a third party such as a commercial manufacturer. This will require complex contract
arrangements that allocate responsibilities (such as quality assurance) and liabilities between parties [39].
And fifth, some of the promising payment-by-performance risk-sharing commissioning schemes for RM ther-
apies, in which payment (and financial risk) is shared between partners, will require coordinated data-collection
infrastructures at clinical sites, so that payment can be aligned with specific clinical outcomes. Such data infras-
tructures can be expensive and time-consuming to establish and determining who collects data and tracks patient
outcomes often difficult to resolve [40].
The adoption of RM technologies within hospitals and clinics thus presents a range of challenges that relate
to supporting infrastructures and skill base, regulatory requirements, commissioning and reimbursement. It has
been argued elsewhere, for example [41], that the successful adoption of RM will require the establishment of
’innovation niches’: protected, organizational arrangements and technical infrastructures that provide a seed-bed
for the product or technique to be nurtured, so that a further evidence based can be generated, and so that logistical
arrangements and other supporting systems can be trialed and consolidated [42]. The following section will provide
an overview of recent proposals to establish formal innovation niches for RM in the UK, in the form of a network
of specialist centers for cell and gene therapy treatments [9,11]. There are, it will be argued, important precedents
and opportunities for these proposed centers in the existing UK healthcare system.
Advanced therapy treatment centers: precedents & opportunities
The Regenerative Medicine Expert Group report (2015) and more recently the Advanced Therapies Manufacturing
(ATM) Taskforce Report (2017) have called for the establishment of specialist centers for delivering cell and gene
therapies within the UK [8,11]. The ATM Taskforce has recommended that £30 million in new government funding
be administered by Innovate UK to establish the centers via a competitive process. This would encourage the
consolidation of resources and expertise around designated hospitals that already have extensive experience in
developing and trialing RM therapies [11]. Possible candidates are likely to include sites that include hospitals in
Edinburgh, Newcastle and London (University College London Hospital, Kings, Guy’s and St Thomas’ Hospitals,
Royal Free Hospital, UK), all of which have made strategic investments in RM, and have access to GMP facilities
with expertise in cell, tissue and gene-based product development. It is envisaged that the funding would be used
for refurbishing infrastructure rather than the construction of new buildings.
The rationale for establishing the network of centers is that they would provide the necessary stability that
would enable the trialing and consolidation of supply chains, data collection infrastructures and the trialing and
consolidation of appropriate business models for industrial partners [11]. They would act as test beds or exemplars
within the RM field, which could then be extended at a national level and give stakeholders and potential investors a
clearer pathway to commercial and clinical success. It is envisaged that the centers would be carefully coordinated to
ensuring the sharing of best practice, and the ATM report also argues that the centers would constitute partnerships
between NHS organizations and industry: the NHS organizations would provide the clinical expertise and support
patient access, while industrial partners would provide manufacturing and logistical expertise [11].
The substantive dimensions of this network of centers, and indeed the criteria according to which competitive
funding might be allocated, have yet to be elucidated. In order to prompt discussion on these issues, here we highlight
some important precedents and opportunities within existing healthcare arrangements in the UK and elsewhere.
The most important are existing hematological services, and particularly the NHS Blood and Transplant (NHSBT)
service and the Scottish National Blood Transfusion Service. These represent an important reservoir of infrastructure
and expertise for procurement and transportation of cells and tissues, for administering cell-based treatments and
for preparing patients [39]. They also represent a vital reservoir of expertise in dealing with Human Tissues Authority,
Medicines and Healthcare products Regulatory Agency and EMA regulatory requirements, including those relating
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to GMP licensing. Lowdell and Thomas, for example, provide an account of an existing arrangement at the Royal
Free Hospital in which transported cryopreserved materials are received by hematology staff with relevant QA and
handling expertise rather than by the hospital pharmacist [39]. Several of the more advanced and highly promising
developments in RM, such as gene therapy for severe combined immunodeficiency and chimeric antigen receptor
T-cell (CAR-T cell) therapies for blood cancers, have emerged from these services and have significant homologies
with routinely offered hematopoietic stem cell transplantations. NHSBT and Scottish National Blood Transfusion
Service have also been partners in other projects in RM – a notable example being the NHSBT’s collaboration with
Videregen on the bioengineered trachea [43]. Existing hematological and transplantation services, therefore, provide
an important springboard for establishing specialist cell and gene therapy treatment centers. There will also likely
be a role for the national NHS Clinical Research Networks who may, through the National Institute for Health
Research, provide a route through which to help embed RM within the NHS more broadly.
Existing risk-sharing schemes for high-cost drugs are also highly relevant for the proposed network of treatment
centers. The UK has several such schemes for high-cost oncology drugs and recently a heart drug [44], and in
Scotland, some orphan drugs and hemophilia treatments are also funded in this way [45]. Importantly, the integrated
electronic patient records system within Scotland allows for ‘payment by performance’ schemes, in which payments
to manufacturers are aligned with clinical outcomes. Similar schemes are used in other European countries,
particularly Italy [46]. Most notably, this includes the EMA-approved Strimvelis, a gene therapy for adenosine
deaminase severe combined immunodeficiency (ADA-SCID) with a cost of over US$600,000 per patient. The
manufacturer GSK supplies the treatment with a ‘money back guarantee’, so that GSK is paid for only those patients
who are successfully treated [47]. Such funding arrangements (and the supporting clinical outcome data collection
infrastructure they require) provide an important precedent for RM [44], and particularly the proposed advanced
therapy treatment centers. Indeed, it is likely that many of the initial therapies offered by these centers will be
high cost and targeted for rare indications, much like those treatments that are already supported via ’specialized
commissioning’.
Another important (and perhaps less obvious) precedent for implementing highly disruptive RM technologies is
the current establishment of the UK Proton Beam Therapy program in the UK [48]. Two proton beam therapy centers
are being developed, and the program has involved the development of substantial ‘bricks and mortar’ infrastructure,
new staff training regimes and new patient pathways. The UK government has committed £250 million to the
program [49]. It has required coordination from a range of agencies within the healthcare system, the Department
of Health, NHS Foundation Trusts, Health Education England and others. It may be that implementing some of
the more disruptive RM therapies will require a similar level of upfront investment and coordination.
The important role of patients & patient charities
An additional issue that needs to be considered is the role of patients and patient charities in informing the
design of clinical services for RM therapies. Current healthcare policy in the UK, as in many OECD countries,
is advocating patient-centered approaches [28], and there is evidence illustrating the benefits of having patient
involvement in the organizational design of clinical services [50–52]. There are some particular issues that might
warrant patient perspectives when establishing the network of cell and gene therapy treatment centers, and the
implementation of RM more generally. These include the geographical distribution of treatment centers. While
in the short term it is necessary to consolidate resources at a few specialist centers, in the longer term, when
ideally treatments become available for more prevalent indications, it is important to avoid exacerbating already
problematic regional inequalities. Patient involvement can also be used to help ensure that the clinical outcome
measures used in specialist centers are relevant: do the outcome measures, in other words, capture clinical changes
that are important for patients and their families? It is also important to ensure that services have a means of
providing appropriate support mechanisms for managing the psychosocial dimensions of illness and treatment.
This may mean ensuring that specialist treatment centers have productive links with community health and social
services. Such a patient-centered approach recognizes that promising new RM therapies – as with many promising
therapies [53] – should be seen as part of a regime of care, rather than as some sort of technological fix.
IR for RM
Such precedents and opportunities need to be considered when assessing the suitability of potential clinical sites for
implementing RM therapies, as do the adoption challenges outlined in earlier sections. These considerations are
important elements of what can be defined as the IR of a clinical context. The concept has been developed within
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Box 1. The propositions underpinning the concept of institutional readiness.
 Adoption is the result of active, ongoing work by creative agents (such as front-line clinicians, hospital managers,
administrators) who are constrained by bounded rationality and limited resources
 Diverse agents need to be actively enrolled in adopting a technology or technique. This means that their
expectations and workloads need to be explicitly aligned
 Adoption requires regular opportunities for relevant staff to engage in relexive evaluation of the technology
and the service. This helps staff to be re-enrolled in the adoption process
Table 1. Criteria for assessing the institutional readiness of clinical delivery sites for regenerative medicine therapies.
Criteria relating to the regenerative medicine technology or technique Criteria relating the potential site of clinical delivery
Prevalence of target indication – Capacity to treat expected patient cohort
– Existing expertise in disease area
Complexity of intervention – Clinical skills for preparing patients and administering treatments
– Opportunities for staff training
– Appropriate infrastructure for administering treatments (e.g., beds)
– Skills in logistical coordination or resources
– Expertise in interdisciplinarity
Level of patient association/charity support for the therapy Opportunities for meaningful patient involvement in organizational design and
service improvement
Perceptions of technology/technique, for example, does it have a high proile? – Goal alignment of front clinicians, administrators, managers and other actors
– Flexibility for aligning work schedules
Place and mode of manufacturing: centralized manufacturing? Redistributed
manufacturing (i.e., hub and spoke and/or hospital-based)?
– Access to GMP-licensed facility (and associated GMP expertise)
– Access to and capacity for appropriate bioprocessing systems
– Appropriately trained qualiied persons and appropriate quality assurance staff
and systems
Can costs and clinical outcomes be reliably monitored? – Capacity and resource for data-collection infrastructures for monitoring outcomes
– Allocated time for monitoring and for stakeholders to engage in collective
evaluation
Quality of supporting evidence of clinical utility and cost–effectiveness Agreement among stakeholders on what constitutes ‘evidence’ of success
Cost Ability to secure appropriate funding (via established commissioning structures or
charitable assistance)
the REGenableMED project, and is based on systematic study of the political and social dimensions of innovation
in RM. Specifically, IR within healthcare can be defined as:
"Whether, and if so, how far, an organization needs to adapt to embrace a new technology".
The IR concept is thus premised on the now commonly held assumption that technology adoption is a prob-
lematic aspect of the innovation process, rather than being a straightforward deployment of a fully developed
product or practice. Drawing on May’s and Greenhalgh et al.’s analyses of technology adoption and innovation in
healthcare [30,31,35,54], it is based on the propositions outlined in Box 1.
The value of this approach is that it points to those processes and contexts that shape technology (clinical)
adoption, and so how novel organizational forms, such as the advanced therapy treatment centers can be configured
to adopt RM manufacture and implementation most efficiently. IR can thus be used as an analytical frame for
examining potential clinical sites for the proposed network of cell and gene therapy centers, and indeed for the
longer term (and hopefully more widespread) implementation of RM technologies within the healthcare system.
In light of the specific adoption challenges related to RM and the precedents and opportunities noted above, Ta-
ble 1 provides an overview of relevant general criteria for assessing IR for specific RM technologies and techniques.
Given that RM represents a diverse field of technologies and techniques requiring vastly different skill sets and sup-
porting infrastructures, the IR of a clinical site will likely differ substantially for any given technology or technique.
Additionally, some criteria, such as ‘quality of supporting evidence of clinical utility and cost–effectiveness’, relate
more to the technology or technique – these are listed in the left column. Other criteria, such as ‘capacity to treat
expected patient cohort’, relate more to the potential site of adoption – these are presented on the right column.
The criteria listed traverse the regulatory, commissioning and technological dimensions of technology adoption.
Some of the criteria relate to any disruptive therapeutic innovation. These include the site’s existing expertise in
specific disease areas; its capacity to treat an expected disease cohort; and the ability to secure appropriate funding
(via established commissioning structures or charitable assistance). Many of the criteria are likely to be specific to
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advanced cell and gene therapies, such access to a GMP-licensed facility, access to appropriate bioprocessing systems
and necessary skill sets, and appropriately qualified persons and quality assurance mechanisms. In regard to skills,
recent work [55] has shown that there is an inadequate supply of technicians in the area, and especially of those who
have specialist skills in regard to manufacturing ATMPs. Some of the criteria in Table 1 may be less obvious, but
are, in light of the arguments presented above, just as necessary for ensuring successful adoption. These include
the strategic objectives of the organization, the opportunities for meaningful patient involvement in organizational
design and service improvement, and time for relevant staff to engage in monitoring and collective evaluation.
The list of criteria serves as a useful reminder that an RM technology’s market approval and the demonstration
of its clinical- and cost-effectiveness are not, on their own, sufficient to guarantee its adoption: there is a diversity
of challenges that need to be anticipated and managed. The list, then, can be used to identify specific aspects
of a potential clinical site that require targeted investment or management to improve its ‘readiness’ for RM.
Importantly, the list as it is presented here should be seen as highly provisional. As the RM field unfolds, and further
challenges and opportunities are specified in greater depth, new IR criteria are likely to be identified
Conclusion
RM is championed as having the potential to transform healthcare. The realization of its clinical and economic
potential, however, requires initiatives that identify and mitigate various innovation challenges, particularly, as this
paper has argued, those relating to the adoption of RM therapies within clinical delivery contexts such as hospitals
and clinics. As previous social science studies of adoption processes in healthcare have illustrated, these challenges are
diverse and relate to regulation, commissioning and funding, logistical and manufacturing requirements, skill base
and expertise, and professional and institutional interests. There are, as this paper has argued, useful opportunities
for establishing the proposed network of advanced therapy treatment centers (or innovation niches): existing risk-
sharing schemes and the proton beam therapy program are important precedents, and existing hematological and
transplant services represent a valuable ‘spring-board’ for the proposed centers. It is also necessary to ensure that
patient groups are provided with opportunities to meaningfully contribute to the organizational design and service
improvement of RM therapy providers. In light of anticipated adoption challenges and existing precedents and
opportunities, this paper has presented a provisional list of criteria for assessing the IR of potential clinical sites for
delivering an RM technology or technique.
Future perspective: phasing the implementation of RM
Preparing a fuller, more detailed list of IR criteria should be the first step in the initial phase preparing healthcare
systems for the implementation of RM therapies. Given the degree of incommensurability between existing
healthcare delivery infrastructures and RM technologies, and given that most promising developments in RM are
still many years away (if not decades) from receiving marketing authorization, we suggest that it is necessary to plan
the long-term implementation of RM over several phases. In the UK, ‘Phase I’ would involve the identification and
establishment of the network of advanced therapy treatment centers, using the criteria of IR. This would involve
horizon scanning to identify which specific therapies are likely to receive marketing authorization and positive
assessments from Health Technology Assessment agencies (e.g., NICE). Almost certainly, these are likely to be
treatments for relatively small patient groups, or, if larger patient cohorts are envisaged, based on trialing via a
performance-based risk assessment over time. It would also require keeping abreast of developments in bioprocessing
and logistics technologies for which clinical sites will need to be suitably prepared. Ideally, during Phase I, the
network of treatment centers will provide the stability necessary for consolidating supply chain and manufacturing
infrastructures and other supporting technologies, the development and testing of business models, and ultimately
encourage further investment in the field as a whole. Meanwhile, constant horizon scanning will be necessary to
identify promising RM therapies on the ‘near horizon’.
Phase II will involve preparing the healthcare system for the more widespread implementation of RM. It will
begin when horizon scanning has identified promising therapies on the near horizon that cannot be delivered solely
in the network of already-established advanced therapy treatment centers, perhaps due to the prevalence of the
indication. An example of this might be a cell therapy for Parkinson’s, although such a therapy is likely to be many
years away. Ideally, Phase II would involve the application of the IR analysis: to determine the relative impact of
institutional change at the advanced therapy treatment centers and how this varies by disease area; and to then
deploy the approach to envisage the scale of change needed for novel therapies, in order to move to a much higher
order of magnitude in terms of availability. This would entail determining the degree to which systemic changes
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in the healthcare system – a ‘trans-IR’ – are needed. It is important that a range of stakeholders are involved in
these deliberations, notably: relevant patient groups and associations, industry representatives, other experts in
the field such as the Cell and Gene Therapy Catapult, the Department of Health, Health Education England,
Commissioning agencies (such as NICE or Clinical Commissioning Groups) and front-line clinicians and other
staff from NHS foundation trusts. Phase III would begin once the therapy has received a positive health technology
assessment (or has been placed on the list of highly specialized services for specialized commissioning). It would
entail the actual establishment of a wider array of RM therapy providers, and the implementation of the therapy
within these providers. This would require articulating RM with other concurrent developments in biomedical
innovation and its deployment, such as large-scale data collection, precision medicine and new (early) diagnostics.
Establishing a program for the phased implementation of RM may help to provide further confidence among
potential investors. Importantly, the careful, well-planned phasing-in of RM technologies will ensure that scarce
resources are responsibly deployed, that new clinical services provide comprehensive care to patients and their
families, and that already much-stressed healthcare systems are not subjected to unnecessary disruption. There are
good reasons to think that the UK in particular is well prepared for such a responsible implementation of RM: it has
active, well-informed patient charities and associations; it has world-leading hospitals with a commitment to RM; it
has extensive expertise in regulation and commissioning and bioprocessing (The Cell and Gene Therapy Catapult
being a good example of this); there is a commitment to exploring alternative reimbursement and commissioning
models; and there is ongoing research into the day-to-day challenges of developing and implementing RM, for
example [55,56], which will provide an important reservoir of knowledge.
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Executive summary
 Recent reports have identiied the implementation of regenerative medicine (RM) therapies within existing
healthcare delivery systems as a major challenge.
 Hospitals and clinics are structured to provide drug and device-based therapies and surgical interventions, and
may be poorly suited to delivering cell- and gene-based therapies.
 Proactively addressing implementation/adoption challenges will facilitate conidence in the RM ield as a whole.
The challenge of technology adoption in healthcare
 Obdurate infrastructures and routines, multiple professions with conlicting viewpoints, funding pressures and
resource constrains complicate the uptake of new technologies and practices within hospitals.
 Case studies illustrate that proof of clinical and cost–effectiveness are not suficient to guarantee a medical
technology’s adoption.
 RM presents speciic challenges relating to logistics and manufacturing requirements, quality assurance, clinical
expertise and staff training, and commissioning.
Advanced therapy treatment centers: precedents & opportunities
 The successful adoption of RM requires the establishment of specialist innovation niches, such as the proposed
network of advanced therapy centers in the UK.
 Hematological and transplant services and existing payment-by-performance risk-sharing schemes represent
valuable opportunities for adopting RM.
 The current establishment of a UK proton beam therapy program represents an important precedent for
implementing highly disruptive RM therapies in the future.
Institutional readiness for RM
 Institutional Readiness (IR) is useful analytical frame for examining potential clinical sites for cell and gene
therapy treatment centers.
 The notion of IR recognizes that adoption is the result of active, ongoing work by a diverse collective of
stakeholders.
 Criteria for assessing IR traverse issues relating to regulation and commissioning, staff training and skills base,
patient collaboration, bioprocessing and manufacturing.
Future perspective
 It is necessary to plan the long-term implementation of RM over several phases.
 Phase I would involve the identiication and establishment of the network of cell and gene therapy centers, using
the criteria of IR.
 Phase II would involve the application of the IR analysis to envisage the scale of change needed to move to a
much higher order of magnitude in terms of availability.
 Phase III would entail the actual establishment of a wider array of RM providers, and the implementation of the
therapy within these providers.
 Determining precisely when and how to move from one phase to another will require ongoing horizon scanning
and consultation with diverse stakeholders.
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